Hoechst Aktiengesellschaft

Claudia Dax

Stefan Mullner

Compounds of the formula I or II ##STR1## are suitable for the production of pharmaceuticals for the modulation of apoptosis. These compounds can be employed for the treatment of infarct, stroke, neurodegeneration or hypertrophic disorders.

Use of isoxazole and crotonamide derivatives for the modulation of

Compounds of the formula I ##STR1## where one of the radicals R.sup.1 and R.sup.3 is a radical of the formula II --(CH.sub.2).sub.n --A--CH.sub.3 (II) in which A is a covalent bond,--C(O)-- or --C(R.sup.4)(OH)--, are suitable for the production of pharmaceuticals for the modulation of apoptosis. A combination preparation comprising a compound of the formula I and a compound of the formula IV and/or V ##STR2## is suitable for the production of pharmaceuticals for the modulation of apoptosis.

Use of xanthine derivatives for the modulation of apoptosis

Compounds of the formula I ##STR1## where one of the radicals R.sup.1 and R.sup.3 is a radical of the formula II --(CH.sub.2).sub.n --A--CH.sub.3 (II) in which A is a covalent bond, --C(O)-- or --C(R.sup.4)(OH)--, are suitable for the production of pharmaceuticals for the modulation of apoptosis. A combination preparation comprising a compound of the formula I and a compound of the formula IV and/or V ##STR2## is suitable for the production of pharmaceuticals for the modulation of apoptosis.

Growing community of inventors

Gernsheim, Germany

Claudia Dax